{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:46:09Z","timestamp":1789911969608,"version":"4.0.1"},"reference-count":43,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,9,9]],"date-time":"2011-09-09T00:00:00Z","timestamp":1315526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2011,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Human cluster of differentiation (CD) antigen 19 is a B cell\u2010specific surface antigen and an attractive target for therapeutic monoclonal antibody (mAb) approaches to treat malignancies of B cell origin. MEDI\u2010551 is an affinity\u2010optimized and afucosylated CD19 mAb with enhanced antibody\u2010dependent cellular cytotoxicity (ADCC). The results from <jats:italic>in vitro<\/jats:italic> ADCC assays with Natural Killer cells as effector cells, demonstrate that MEDI\u2010551 is effective at lower mAb doses than rituximab with multiple cell lines as well as primary chronic lymphocytic leukaemia and acute lymphoblastic leukaemia samples. Targeting CD19 with MEDI\u2010551 was also effective in several severe combined immunodeficiency lymphoma models. Furthermore, the combination of MEDI\u2010551 with rituximab resulted in prolonged suppression of tumour growth, demonstrating that therapeutic mAbs with overlapping effector function can be combined for greater tumour growth inhibition. Together, the data demonstrate that MEDI\u2010551 has potent antitumour activity in preclinical models of B cell malignancies. The results also suggest that the combination of the ADCC\u2010enhanced CD19 mAb with an anti\u2010CD20 mAb could be a novel approach for the treatment of B cell lymphomas.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2011.08857.x","type":"journal-article","created":{"date-parts":[[2011,9,9]],"date-time":"2011-09-09T17:11:05Z","timestamp":1315588265000},"page":"426-437","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["A glycoengineered anti\u2010CD19 antibody with potent antibody\u2010dependent cellular cytotoxicity activity <i>in vitro<\/i> and lymphoma growth inhibition <i>in vivo<\/i>"],"prefix":"10.1111","volume":"155","author":[{"given":"Elizabeth","family":"Ward","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanette","family":"Mittereder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Kuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary P.","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Dall\u2019Acqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Tedder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kiener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Coyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herren","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahija","family":"Jallal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,9,9]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.6.1424.1424"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.04.005"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-009-0746-z"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2004.08.016"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.015"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/1096-8652(200008)64:4<275::AID-AJH7>3.0.CO;2-Y"},{"key":"e_1_2_7_8_1","first-page":"611","article-title":"Therapy of B\u2010cell lymphoma with anti\u2010CD20 antibodies can result in the loss of CD20 antigen expression","volume":"5","author":"Davis T.A.","year":"1999","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3135"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2007.08.009"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1838"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06155.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood.V83.5.1329.1329","article-title":"Anti\u2010CD19 inhibits the growth of human B\u2010cell tumour lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest","volume":"83","author":"Ghetie M.\u2010A.","year":"1994","journal-title":"Blood"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.51.5.364"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2007.06.151"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.4.726"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01741331"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(04)01490-1"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.168062"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2268"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-177469"},{"key":"e_1_2_7_22_1","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.4049\/jimmunol.147.12.4094","article-title":"Transmembrane signals generated through MHC class II, CD19, CD20, CD39 and CD40 antigens induce LFA\u20101\u2010dependent and \u2010independent adhesion in human B cells through a tyrosine kinase\u2010dependent pathway","volume":"147","author":"Kansas G.S.","year":"1991","journal-title":"Journal of Immunology"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.2165\/11201110-000000000-00000"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.5.3280"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-133108"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm114"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23890"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V70.5.1316.1316"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.004"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2007.02.005"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_2_7_32_1","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4049\/jimmunol.131.1.244","article-title":"B4, a human B lymphocyte\u2010associated antigen expressed on normal, mitogen\u2010activated, and malignant B lymphocytes","volume":"131","author":"Nadler L.M.","year":"1983","journal-title":"Journal of Immunology"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2206"},{"key":"e_1_2_7_34_1","first-page":"700","article-title":"Structural characterization of human Fc fragment engineered for lack of effector functions","volume":"64","author":"Oganesyan V.","year":"2008","journal-title":"Acta Crystallographica"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363080-00005"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2007.08.003"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.25.11558"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199509059636"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0696"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0493"},{"key":"e_1_2_7_41_1","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1182\/blood.V88.4.1188.bloodjournal8841188","article-title":"A phase I study of bolus versus continuous infusion of the anti\u2010CD19 immunotoxin, IgG\u2010HD37\u2010dgA, in patents with B\u2010cell lymphoma","volume":"88","author":"Stone M.J.","year":"1996","journal-title":"Blood"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.05.6291"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V71.1.13.13"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0505539102"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2011.08857.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2011.08857.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T17:59:38Z","timestamp":1697392778000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2011.08857.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,9]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["10.1111\/j.1365-2141.2011.08857.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08857.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,9]]},"assertion":[{"value":"2011-09-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}